ASX ANNOUNCEMENT

Actinogen updated investor presentation

Sydney 21 March 2019: Actinogen Medical (ASX: ACW, 'the Company') is pleased to release an updated Investor Presentation. The presentation will be used to update shareholders, investors and brokers as part of a non-deal roadshow across Australia. The presentation outlines Actinogen's key investment highlights, clinical progress and outlook.

The investor presentation includes further insights into the clinical efficacy endpoints used in the Phase II XanADu clinical trial (refer to slides 16-20). The seven efficacy endpoints are used in the trial to identify the cognitive domains most sensitive to Xanamem's potential efficacy. The endpoints are validated cognitive outcome assessments used in Alzheimer's disease research globally and are recognised and accepted by global regulators. Multiple endpoints de-risk development and there is no reliance on achieving any one individual endpoint to progress clinical development. The totality of the XanADu and additional studies' results, expected by mid-year 2019 (refer to slide 6), will inform the optimal clinical development pathway for Xanamem going forward.

Key Investment Highlights

- **Novel compound:** Actinogen's lead compound Xanamem has a novel mechanism of action targeting excess cortisol production in the brain. This cortisol hypothesis and its potential role in Alzheimer's disease has been validated by multiple independent research.
- **Targeted strategic market focus:** Alzheimer's disease addressable market worth >US$7.5bn with unmet needs and potential upside.
- **Advanced clinical stage asset:** Fully funded advanced clinical stage program with reported positive safety interim analysis of the XanADu Phase II Alzheimer's study, which has completed patient enrolment and is on track for results read-out in 2Q CY2019.
- **Potential value upside:** Well positioned to unlock further value in Alzheimer's disease and other indications, supported by significant big pharma interest.
- **De-risked opportunity:** Initiated nine additional Xanamem-related studies – all studies fully funded and value-adding to Xanamem data-base. Further pipeline development opportunities under evaluation.
- **Experienced leadership and advisors:** Significant drug development and biotech investment experience guided by key opinion leading clinicians and drug discovery teams.

ENDS

Actinogen Medical
Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au
@BillKetelbey

Investor and Media Enquiries
Arthur Chan
WE Buchan
M: +61 2 9237 2805
E: arthurc@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with a multibillion-dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US$250bn and is set to increase to US$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanaHES

XanaHES is a Phase I, randomised, single blinded, central reader blinded, placebo-controlled, dose escalation study to assess the safety and tolerability of Xanamem™ 20mg & 30mg once daily in healthy elderly volunteers. Changes in cognitive performance from baseline to end-of-treatment will be measured as an exploratory efficacy outcome.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. Results are expected in Q2 2019. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.